Q3 2024 EPS Estimates for Fresenius Medical Care AG (NYSE:FMS) Cut by Analyst

Fresenius Medical Care AG (NYSE:FMS) – Investment analysts at Zacks Research dropped their Q3 2024 earnings per share (EPS) estimates for Fresenius Medical Care in a research note issued to investors on Tuesday, May 28th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings per share of $0.43 for the quarter, down from their prior estimate of $0.45. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care’s FY2024 earnings at $1.61 EPS, Q1 2025 earnings at $0.36 EPS, Q4 2025 earnings at $0.52 EPS, Q1 2026 earnings at $0.39 EPS and FY2026 earnings at $1.96 EPS.

Other equities analysts have also recently issued reports about the stock. StockNews.com assumed coverage on shares of Fresenius Medical Care in a research report on Sunday, May 12th. They set a “strong-buy” rating on the stock. Truist Financial lifted their target price on Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a report on Wednesday, May 15th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $32.25.

Fresenius Medical Care Stock Performance

FMS stock opened at $21.28 on Thursday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.50 and a quick ratio of 1.14. Fresenius Medical Care has a fifty-two week low of $16.37 and a fifty-two week high of $27.72. The stock has a market capitalization of $12.48 billion, a PE ratio of 23.90, a price-to-earnings-growth ratio of 1.10 and a beta of 0.95. The company has a 50 day moving average price of $20.31 and a 200 day moving average price of $20.16.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.10. The firm had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.15 billion. Fresenius Medical Care had a return on equity of 5.29% and a net margin of 2.48%.

Fresenius Medical Care Cuts Dividend

The business also recently declared an annual dividend, which will be paid on Monday, June 3rd. Shareholders of record on Monday, May 20th will be given a dividend of $0.437 per share. This represents a dividend yield of 2.35%. The ex-dividend date of this dividend is Friday, May 17th. Fresenius Medical Care’s dividend payout ratio (DPR) is 49.44%.

Hedge Funds Weigh In On Fresenius Medical Care

A number of institutional investors have recently added to or reduced their stakes in the company. Pacer Advisors Inc. increased its position in Fresenius Medical Care by 14,252.1% during the fourth quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock worth $10,173,000 after buying an additional 484,998 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in Fresenius Medical Care by 362.2% in the 3rd quarter. Envestnet Asset Management Inc. now owns 259,033 shares of the company’s stock valued at $5,580,000 after acquiring an additional 202,991 shares during the period. Moran Wealth Management LLC acquired a new stake in Fresenius Medical Care during the 4th quarter valued at $3,247,000. Guardian Capital Advisors LP boosted its position in Fresenius Medical Care by 16.7% during the fourth quarter. Guardian Capital Advisors LP now owns 123,715 shares of the company’s stock worth $2,556,000 after purchasing an additional 17,725 shares during the period. Finally, Partnership Wealth Management LLC bought a new position in Fresenius Medical Care during the fourth quarter worth $2,340,000. 8.25% of the stock is currently owned by institutional investors and hedge funds.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.